Heart block

Public advisory - Donepezil 10 mg tablets: One lot recalled due to possible oversized tablets

Retrieved on: 
Saturday, November 25, 2023
Agonal respiration, Vomiting, Delayed onset muscle soreness, Perspiration, Health Canada, Immediate, Tablet, Somatic symptom disorder, Fatigue, Patient, Pharmacy, Saliva, Neuroleptic malignant syndrome, Alzheimer's disease, Muscle weakness, Caregiver, Convulsion, Agitation, Arrhythmia, Diarrhea, Nausea, Death, Heart block, Pulse, Insomnia, Female, Cramp, Consciousness, Confusion, Coma, Dietary supplement, Medical device, Donepezil

Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.

Key Points: 
  • Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.
  • Health Canada is warning patients and their caregivers that taking an oversized tablet could receive up to three times the intended dose (i.e.
  • Donepezil is a prescription drug used for the symptomatic treatment of mild, moderate, and severe Alzheimer's disease.
  • If your pill bottle of Donepezil 10 mg tablets contains larger-than-normal tablets, or if you are unsure, return it to your pharmacy.

Akron Children's, GlobalCastMD to host conference on cardioneuroablation

Retrieved on: 
Monday, September 11, 2023
Akron Children's Hospital, Learning, Heart, Seizure, Radiation, Sinus node dysfunction, Emergency medicine, Cardiac catheterization, Vagus nerve, Atrial fibrillation, PDT, DRS, Second, Cardiology, Neurology, CNA, EDT, Heart block, Management of atrial fibrillation, Patient, Physician, Electrophysiology, Fluoroscopy, Hospital, Reflex syncope, Heart rate, Pediatrics, Paulo, Medical device

AKRON, Ohio, Sept. 11, 2023 /PRNewswire/ -- Akron Children's Hospital and GlobalCastMD will co-host the Second World Congress on Cardioneuroablation, a live, virtual conference, on Oct. 21 from 11 a.m. EDT, 8 a.m. PDT.

Key Points: 
  • AKRON, Ohio, Sept. 11, 2023 /PRNewswire/ -- Akron Children's Hospital and GlobalCastMD will co-host the Second World Congress on Cardioneuroablation, a live, virtual conference, on Oct. 21 from 11 a.m. EDT, 8 a.m. PDT.
  • Dr. Pachón is director of the São Paulo Heart Hospital Arrhythmia Service in São Paulo, Brazil.
  • Dr. Clark is director of electrophysiology at Akron Children's Hospital in Akron, Ohio.
  • This conference is suggested for not only electrophysiologists and cardiologists, but also neurologists, general medicine practitioners, emergency medicine physicians, pediatricians, and allied health professionals.

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023
Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Hypersensitivity, Cholinesterase, Nausea, Bethanechol, Bradycardia, Peptic ulcer disease, Asthma, Neuromuscular blocking agents, Cholinergic, Partnership, Alzheimer's disease, Diarrhea, Gastrointestinal tract, IQVIA, Roflumilast, Skin, History, Orthostatic syncope, CNS, Heart block, Dementia, Tablet, Anesthesia, Vomiting, Enzyme inhibitor, Incidence, Patient, Chloride, Gastrointestinal bleeding, Nonsteroidal anti-inflammatory drug, FDA, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cholinesterase inhibitor, Safety, Food, Caregiver, Pharmaceutical industry, Residential care, Dietary supplement, Corium, Donepezil, Lotus

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

Retrieved on: 
Tuesday, August 9, 2022
People, Woman, Regeneration, U.S. Securities and Exchange Commission, Sustainability Accounting Standards Board, CEO, GLOBE, R, Forward-looking statement, Private Securities Litigation Reform Act, Regenerative medicine, Board, Medicine, Security (finance), Ernst & Young Entrepreneur of the Year Award, AATB, Patient, Therapy, Bone marrow, Company, Scientific Leadership, Skin, Biotechnology, Infection, Smith, World, Organization, Goal, Investor, National Marrow Donor Program, IPO, Osiris Therapeutics, California Institute for Regenerative Medicine, Heart block, Management, Pharmaceutical industry, Osiris, Transplant

SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.

Key Points: 
  • SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.
  • Since creating Aziyo in 2015, Randy and I have worked together to build a company where regenerative medicine is used to its full potential, said Kevin Rakin, co-founder and executive chairman.
  • Randy is a visionary leader with a track record of creating significant shareholder value in regenerative medicine.
  • The Board and I look forward to partnering with Randy as we make his vision for this company a reality.

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

Retrieved on: 
Wednesday, April 6, 2022
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Risk, Hypoglycemia, Therapy, Meropenem, First-degree atrioventricular block, Clonidine, Blood pressure, Cardiac arrest, NYHA, III, Allergy, Moyamoya disease, Diabetes, Angina, Diltiazem, Hyperthyroidism, Vaborbactam, Cardiogenic shock, AstraZeneca, Heart, Patient, Hypertension, Bradycardia, Peripheral artery disease, CEO, Adrenaline, Sinus node dysfunction, Pheochromocytoma, LLC, Heart block, Acquisition, Stroke, Verapamil, Injection, Castleman disease, Heart failure, Purkinje fibers, Digitalis, FDA, Minocycline, Infarction, Hypersensitivity, Pharmaceutical industry, Medical device, Melinta Therapeutics

We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.

Key Points: 
  • We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.
  • We are extremely proud of our work to provide access to this lifesaving medication, said Michael Anderson, CEO, New American Therapeutics.
  • Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
  • At Melinta, were visionaries dedicated to innovation while staying grounded in what matters most: patients.

Zio® by iRhythm Shows Significantly Higher Documentation of Atrial Fibrillation and Atrial Flutter Compared to Holter Monitors, Event Monitors

Retrieved on: 
Monday, February 28, 2022
GLOBE, ECG, PPM, AJC, Left bundle branch block, Atrial fibrillation, Arrhythmia, Supraventricular tachycardia, Health, Prevalence, NASDAQ, Kaiser Permanente, Holter, Diagnosis, AF, AFL, JACC, Atrial flutter, Holter monitor, Heart block, Aortic valve, Trial of the century, American Journal, Index, Hospital, Cleveland Clinic, Bradycardia, SAN, TAVR, Patient, Technology, American College, The American Journal of Cardiology, Journal, IRTC, MD, Research, Zio, BBB, Tachycardia, Medical device, Medical imaging

This latest clinical research further validates that monitoring with Zio by iRhythm leads to better diagnostic yield and aids in more accurate diagnoses.

Key Points: 
  • This latest clinical research further validates that monitoring with Zio by iRhythm leads to better diagnostic yield and aids in more accurate diagnoses.
  • The KP-Rhythm2 study examined the efficacy of Zio XT, Holter monitors, and event monitors.
  • Zio XT was associated with significantly higher documentation1 of AF/AFL -related supraventricular tachycardias and non-sustained ventricular tachycardia than both 24-hour Holter and 30-day event monitoring.
  • Zio XT also identified numerically more new AF/AFL compared to 30-day event, although differences were not statistically significant (p = 0.07).

B. Braun Announces Nationwide Availability of Magnesium Sulfate Family of Products

Retrieved on: 
Wednesday, December 8, 2021
Infant, Central nervous system, Magnesium sulfate, PAB, B. Braun, Risk, Pregnancy, Contraindication, Medical Affairs Bureau, PVC, Therapy, Pain management, Dialysis, CAPS, Woman, USP, Toxemia, Death, Convulsion, Liver, Platelet, Patient, Thornburgh v. American College of Obstetricians & Gynecologists, Corporation, Urine, American College, Company, Eclampsia, Myasthenia gravis, Foundation, Approximation error, Glucose, DEHP, Multimedia, ACOG, Lists of diseases, Treatment, Heart block, Pharmacist, Diabetic coma, Preterm birth, Gynaecology, Mother, Seizure, Medical device, Birth control, Aluminium, Pharmaceutical industry, Television

Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."

Key Points: 
  • Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."
  • Someof the many characteristics of B. Braun's Magnesium Sulfate products include:
    Domestically manufactured and sourced: In addition to being manufactured in Irvine, California, B. Braun's Magnesium Sulfate products are produced with American-made active pharmaceutical ingredients, helping ensure consistent supply levels.
  • Eco-friendly Packaging: B. Braun's Magnesium Sulfate products do not require an overwrap like other ready-to-use Magnesium Sulfate pre-mixed bags, reducing landfill waste.
  • Ready-to-Use Pre-Mixed Bags: Doses include Magnesium Sulfate in 5% Dextrose, 1 g/100 mL, Magnesium Sulfate in Water, 2 g/50 mL, Magnesium Sulfate in Water, 4 g/50 mL, and Magnesium Sulfate in Water, 4 g/100 mL.

Experience with BioTrace Medical's Tempo Temporary Pacing Lead in Management of Bradyarrhythmia Presented at the American Heart Association's Scientific Sessions 2021

Retrieved on: 
Monday, November 15, 2021
Tempo, Maintenance, Bradycardia, Heart block, Technology, Methodist Hospital, PCT, American Heart Association, Trial of the century, Pleural effusion, Male, Patient, Science, Medical device

MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire-PRWeb/ -- BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company's Tempo Temporary Pacing Lead was featured in a clinical study presented at the American Heart Association's Scientific Sessions 2021, held November 13-15 in Orlando, Florida.

Key Points: 
  • MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire-PRWeb/ -- BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company's Tempo Temporary Pacing Lead was featured in a clinical study presented at the American Heart Association's Scientific Sessions 2021, held November 13-15 in Orlando, Florida.
  • The study, titled " A Retrospective Analysis of a Single-Center Experience with the Tempo Temporary Pacing Lead in Management of Bradyarrhythmia and Other Cardiac Electrophysiology Procedures ", analyzed a series of twelve consecutive patients who underwent Tempo Lead placement for temporary pacing at OhioHealth Riverside Methodist Hospital in Columbus, Ohio.
  • Twelve consecutive patients (83% male, mean age 71.3 10.1 years) who underwent Tempo Lead placement for temporary pacing were retrospectively reviewed (75% symptomatic bradyarrhythmia, 25% other indications including permanent lead malfunction, permanent pacemaker infection, and complete heart block.)
  • With U.S. FDA clearance and CE certification, the Tempo Lead is the only active fixation temporary pacing lead available in the world.

Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

Retrieved on: 
Thursday, August 5, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chief executive officer, Efficiency, Heart block, Cardiac arrest, Injury, Cardiogenic shock, Heart, Septic shock, Hypovolemia, Isoprenaline, Patient, Perfusion, Food and Drug Administration, AP, Biotechnology, Anesthesia, Bronchospasm, Medical device, Fine chemical, Amring Pharmaceuticals Inc., SEVER Life Sciences B.V., AMRING PHARMACEUTICALS INC., SEVER LIFE SCIENCES B.V.

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.
  • "We are pleased to add Isoproterenol Hydrochloride Injection USP to our generics portfolio, this product brings long term value to patients and customers in our target markets, stated Daniel Carbery, President and CEO of Amring.
  • We look forward to realizing the benefits of this, and other product launches and future business development activities in 2021.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market.